Entera Bio Ltd
NASDAQ:ENTX
Intrinsic Value
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. [ Read More ]
The intrinsic value of one ENTX stock under the Base Case scenario is 0.16 USD. Compared to the current market price of 1.67 USD, Entera Bio Ltd is Overvalued by 91%.
Valuation Backtest
Entera Bio Ltd
Run backtest to discover the historical profit from buying and selling ENTX stocks based on their intrinsic value.
Analyze the historical link between intrinsic value and market price to make more informed investment decisions.
Fundamental Analysis
Balance Sheet Decomposition
Entera Bio Ltd
Current Assets | 11.3m |
Cash & Short-Term Investments | 11m |
Other Current Assets | 238k |
Non-Current Assets | 508k |
PP&E | 488k |
Other Non-Current Assets | 20k |
Current Liabilities | 1.1m |
Accounts Payable | 83k |
Accrued Liabilities | 1m |
Non-Current Liabilities | 288k |
Other Non-Current Liabilities | 288k |
Earnings Waterfall
Entera Bio Ltd
Revenue
|
0
USD
|
Operating Expenses
|
-8.9m
USD
|
Operating Income
|
-8.9m
USD
|
Other Expenses
|
2k
USD
|
Net Income
|
-8.9m
USD
|
Free Cash Flow Analysis
Entera Bio Ltd
What is Free Cash Flow?
ENTX Profitability Score
Profitability Due Diligence
Entera Bio Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
Score
Entera Bio Ltd's profitability score is 19/100. The higher the profitability score, the more profitable the company is.
ENTX Solvency Score
Solvency Due Diligence
Entera Bio Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Entera Bio Ltd's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ENTX Price Targets Summary
Entera Bio Ltd
According to Wall Street analysts, the average 1-year price target for ENTX is 10.2 USD with a low forecast of 10.1 USD and a high forecast of 10.5 USD.
Ownership
ENTX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Shareholder Return
ENTX Price
Entera Bio Ltd
Average Annual Return | -0.22% |
Standard Deviation of Annual Returns | 107.68% |
Max Drawdown | -93% |
Market Capitalization | 59.2m USD |
Shares Outstanding | 35 481 300 |
Percentage of Shares Shorted | 0.08% |
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Entera Bio Ltd. is a clinical-stage biopharmaceutical company, which focuses on the development and commercialization of orally delivered large molecule therapeutics. The firm conducts clinical trials on its proprietary technology, which allows oral delivery of large molecules and biologics while enhancing their absorption in the gastrointestinal (GI) tract. Entera Bio Ltd's technology addresses the major problems of oral drug delivery of large molecule active pharmaceutical ingredients (APIs). Most large molecules cannot be administered orally as they are not readily absorbed by the gastrointestinal tract and are rapidly degraded by a myriad of enzymes and acids in the gastrointestinal tract. The Company’s proprietary technologies act synergistically to transport and protect large molecules. The firm develops drugs for hypoparathyroidism, osteoporosis and bone healing.
Contact
IPO
Employees
Officers
The intrinsic value of one ENTX stock under the Base Case scenario is 0.16 USD.
Compared to the current market price of 1.67 USD, Entera Bio Ltd is Overvalued by 91%.